Serum IL-9 levels and sublingual immunotherapy: Preliminary report

Giorgio Ciprandi, M. De Amici, G. L. Marseglia

Research output: Contribution to journalArticle

Abstract

Th9 is a new T cell subset characterized by IL-9 production. It has been reported that serum IL-9 levels are related with symptom severity in patients with allergic rhinitis (AR). This study is aimed at investigating whether serum IL-9 may be modulated by sublingual immunotherapy (SLIT) in patients with persistent AR due to Parietaria allergy. Twenty-one AR patients (9 males, median age 41 years) successfully treated with SLIT and 52 AR patients (25 males, median age 34 years) treated only with drugs were evaluated during the pollen season. Serum IL-9 was dosed in all patients. SLIT-treated patients showed significantly lower serum IL-9 levels than untreated AR patients (p

Original languageEnglish
Pages (from-to)295-297
Number of pages3
JournalJournal of Biological Regulators and Homeostatic Agents
Volume25
Issue number2
Publication statusPublished - Apr 2011

Fingerprint

Sublingual Immunotherapy
Interleukin-9
Serum
Parietaria
T-Lymphocyte Subsets
Pollen
Hypersensitivity
Allergic Rhinitis

Keywords

  • Allergic rhinitis
  • Pollen allergy
  • Serum IL-9
  • Sublingual immunotherapy

ASJC Scopus subject areas

  • Oncology
  • Endocrinology, Diabetes and Metabolism
  • Physiology (medical)
  • Immunology and Allergy
  • Immunology
  • Endocrinology
  • Physiology
  • Cancer Research

Cite this

Serum IL-9 levels and sublingual immunotherapy : Preliminary report. / Ciprandi, Giorgio; De Amici, M.; Marseglia, G. L.

In: Journal of Biological Regulators and Homeostatic Agents, Vol. 25, No. 2, 04.2011, p. 295-297.

Research output: Contribution to journalArticle

@article{529517322a76415e8b4b99761dfb30b8,
title = "Serum IL-9 levels and sublingual immunotherapy: Preliminary report",
abstract = "Th9 is a new T cell subset characterized by IL-9 production. It has been reported that serum IL-9 levels are related with symptom severity in patients with allergic rhinitis (AR). This study is aimed at investigating whether serum IL-9 may be modulated by sublingual immunotherapy (SLIT) in patients with persistent AR due to Parietaria allergy. Twenty-one AR patients (9 males, median age 41 years) successfully treated with SLIT and 52 AR patients (25 males, median age 34 years) treated only with drugs were evaluated during the pollen season. Serum IL-9 was dosed in all patients. SLIT-treated patients showed significantly lower serum IL-9 levels than untreated AR patients (p",
keywords = "Allergic rhinitis, Pollen allergy, Serum IL-9, Sublingual immunotherapy",
author = "Giorgio Ciprandi and {De Amici}, M. and Marseglia, {G. L.}",
year = "2011",
month = "4",
language = "English",
volume = "25",
pages = "295--297",
journal = "Journal of Biological Regulators and Homeostatic Agents",
issn = "0393-974X",
publisher = "Biolife s.a.s.",
number = "2",

}

TY - JOUR

T1 - Serum IL-9 levels and sublingual immunotherapy

T2 - Preliminary report

AU - Ciprandi, Giorgio

AU - De Amici, M.

AU - Marseglia, G. L.

PY - 2011/4

Y1 - 2011/4

N2 - Th9 is a new T cell subset characterized by IL-9 production. It has been reported that serum IL-9 levels are related with symptom severity in patients with allergic rhinitis (AR). This study is aimed at investigating whether serum IL-9 may be modulated by sublingual immunotherapy (SLIT) in patients with persistent AR due to Parietaria allergy. Twenty-one AR patients (9 males, median age 41 years) successfully treated with SLIT and 52 AR patients (25 males, median age 34 years) treated only with drugs were evaluated during the pollen season. Serum IL-9 was dosed in all patients. SLIT-treated patients showed significantly lower serum IL-9 levels than untreated AR patients (p

AB - Th9 is a new T cell subset characterized by IL-9 production. It has been reported that serum IL-9 levels are related with symptom severity in patients with allergic rhinitis (AR). This study is aimed at investigating whether serum IL-9 may be modulated by sublingual immunotherapy (SLIT) in patients with persistent AR due to Parietaria allergy. Twenty-one AR patients (9 males, median age 41 years) successfully treated with SLIT and 52 AR patients (25 males, median age 34 years) treated only with drugs were evaluated during the pollen season. Serum IL-9 was dosed in all patients. SLIT-treated patients showed significantly lower serum IL-9 levels than untreated AR patients (p

KW - Allergic rhinitis

KW - Pollen allergy

KW - Serum IL-9

KW - Sublingual immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=80052871597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052871597&partnerID=8YFLogxK

M3 - Article

C2 - 21880201

AN - SCOPUS:80052871597

VL - 25

SP - 295

EP - 297

JO - Journal of Biological Regulators and Homeostatic Agents

JF - Journal of Biological Regulators and Homeostatic Agents

SN - 0393-974X

IS - 2

ER -